周三，TD Cowen重申了对Hims & Hers Health, Inc.（NYSE: HIMS）股票的买入评级，维持28.00美元的目标价。该公司的评论主要集中在最近FDA与外包设施协会（OFA）之间关于药物tirzepatide的法律进展。FDA提议的联合状态报告定于2024年11月21日发布，这可能会澄清该药物的供应状况。 TD Cowen的分析师强调了即将发布的报告的重要性及其对市场的 ...

根据最近的SEC文件显示，Hims & Hers Health, Inc. (NYSE:HIMS)的首席运营官Melissa Baird近期出售了她持有的公司股票的一大部分。Baird于2023年11月18日总共出售了58,750股，获得约124万美元。这些股票的售价在每股20.4821美元至21.3026美元之间。

Celebrity momager Kris Jenner has always been mindful of her image, first as the wife of two highly successful men and now as ...

Hims & Hers Health's stock dropped 25% due to Amazon’s competition. Learn why HIM stock's 38% upside and strong growth make ...

Hims & Hers Health, Inc. (“Hims & Hers”) (NYSE: HIMS), the leading health and wellness platform, today announced Deb Autor, ...

Hims & Hers offers personalized telehealth services, with a stock price that reflects high-growth potential. See why we ...

Should you invest $1,000 in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The ...

Hims & Hers Health Inc. shares tumbled 22% Thursday, on concerns that Amazon.com Inc.’s latest push into healthcare will ...

Shares of Hims & Hers Health slumped 15% on Thursday after Amazon.com launched a rival service that offers upfront pricing ...

Hims & Hers Health ( HIMS, Financials) shares slumped 24.5% on Thursday as Amazon ( AMZN, Financials) expanded into hair loss ...

Shares of Hims & Hers Health jumped after the company added former Food and Drug Administration official Deb Autor to its board. The stock was up 8.8% at $21.02 in Monday trading. Shares have doubled ...

Shares of Hims & Hers slid after Amazon.com said it would offer cheap treatments for concerns like hair loss, skin care and ...